Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Eucalyptol

What is Eucalyptol?

CAS No: 470-82-6

Eucalyptol is a compound of defined chemical structure and pharmaceutical significance whose toxicological characterisation supports health-based exposure limit derivation for pharmaceutical manufacturing occupational safety and cross-contamination control. The relationship between molecular structure and biological potency—assessed through structure-activity relationship analysis and experimental pharmacological and toxicological data—determines the OEB classification and the engineering containment requirements governing manufacturing operations involving Eucalyptol.

Reproductive and developmental toxicity findings for Eucalyptol receive an additional severity factor consideration in PDE derivation, because pharmaceutical patient populations frequently include women of childbearing potential and, in some indications, pregnant patients.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Eucalyptol, also known as 1,8-cineole, is a monoterpene ether that is the main constituent of eucalyptus oil and is used as a flavor, a fragrance, and an ingredient in some medicinal products. A toxicological assessment helps define suitable exposure limits and handling controls for workers.

A PDE or ADE sets a health-based limit on daily exposure to Eucalyptol from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Yes. A limit does not depend on whether a substance is a finished drug. When direct data are limited, a documented approach can use read-across from related compounds, structure-based evaluation, and the information that does exist. Each assumption should be stated clearly, so reviewers can judge whether the resulting limit is scientifically justified for the intended use.

It can. Handling a dry powder may create airborne dust, while a solution or a granulated material may present a different exposure profile. The occupational assessment should therefore consider the form in which the substance is handled, the operation involved, and the controls in place, so that the recommended measures match the real task.

Uncertainty factors account for differences between test species and humans, variability between individuals, study duration and quality, and gaps in the available data. Each factor must be scientifically justified and documented so reviewers can follow how the final health-based limit was reached.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Eucalyptol in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Each step is reviewed for how exposure could occur, for example through dust, vapor, splashes, or contact with equipment surfaces. The assessment links the exposure limit to the task, its duration, and the controls available, such as containment, ventilation, and protective equipment. This helps organizations match handling measures to the real operations in their facility.

The OEL gives a scientific benchmark for evaluating workplace exposure. Combined with exposure monitoring, engineering controls, and safe handling procedures, it helps organizations manage inhalation risk during operations such as dispensing, granulation, and cleaning. It should sit within a broader occupational risk assessment.

An assessment should be reviewed when new toxicological data become available, when the intended use or handling conditions change, or when relevant guidance is updated. Periodic review keeps the health-based limit aligned with current scientific knowledge and regulatory expectations. Any change to the conclusion should be documented with a clear rationale for the revision.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Eucalyptol to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo